Literature DB >> 3983385

Metabolic bone disease in pseudohypoparathyroidism: radiologic features.

M I Burnstein, S R Kottamasu, J M Pettifor, E Sochett, B I Ellis, B Frame.   

Abstract

We reviewed the radiographs of six patients with pseudohypoparathyroidism (PHP) manifested by variable renal and skeletal resistance to parathyroid hormone (PTH). Features compatible with hyperparathyroid bone disease, osteomalacia, and rickets were observed. Skeletal changes of hyperparathyroidism included (a) subperiosteal bone resorption, (b) radiolucent lesions, caused by either brown tumors or bone cysts, (c) slipped capital femoral epiphyses, (d) focal areas of osteosclerosis, (e) periosteal neostosis, and (f) osteopenia with reduced cortical and trabecular bone volume. Histologic bone features were compatible with osteitis fibrosa in all patients, which suggests that the skeleton responded to the bone-remodeling effects of PTH despite hormonal resistance at other target sites. Skeletal changes of rickets included metaphyseal irregularities, cupping, and widening of the growth plates. Osteomalacia was indicated by Looser zones in one patient and confirmed by histologic evidence in three patients.

Entities:  

Mesh:

Year:  1985        PMID: 3983385     DOI: 10.1148/radiology.155.2.3983385

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  14 in total

Review 1.  Clinical spectrum and pathogenesis of pseudohypoparathyroidism.

Authors:  M A Levine
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Pseudohypoparathyroidism presenting with bony deformities resembling rickets.

Authors:  Anurag Bajpai; Jyoti Sharma; Pankaj Hari; Arvind Bagga
Journal:  Indian J Pediatr       Date:  2004-04       Impact factor: 1.967

3.  Brown tumor in secondary hyperparathyroidism, causing progressive paraplegia.

Authors:  J M Pumar; M Alvarez; A Perez-Batallon; J Vidal; J Lado; A Bollar
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

4.  A Large Inversion Involving GNAS Exon A/B and All Exons Encoding Gsα Is Associated With Autosomal Dominant Pseudohypoparathyroidism Type Ib (PHP1B).

Authors:  Giedre Grigelioniene; Pasi I Nevalainen; Monica Reyes; Susanne Thiele; Olta Tafaj; Angelo Molinaro; Rieko Takatani; Marja Ala-Houhala; Daniel Nilsson; Jesper Eisfeldt; Anna Lindstrand; Marie-Laure Kottler; Outi Mäkitie; Harald Jüppner
Journal:  J Bone Miner Res       Date:  2017-02-24       Impact factor: 6.741

Review 5.  Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues.

Authors:  Giovanna Mantovani; Anna Spada; Francesca Marta Elli
Journal:  Nat Rev Endocrinol       Date:  2016-04-22       Impact factor: 43.330

6.  Osteoma cutis as the presenting feature of albright hereditary osteodystrophy associated with pseudopseudohypoparathyroidism.

Authors:  Ki-Heon Jeong; Bark-Lynn Lew; Woo-Young Sim
Journal:  Ann Dermatol       Date:  2009-05-31       Impact factor: 1.444

Review 7.  Albright's hereditary osteodystrophy.

Authors:  L C Wilson; R C Trembath
Journal:  J Med Genet       Date:  1994-10       Impact factor: 6.318

8.  Osteosclerosis in two brothers with autosomal dominant pseudohypoparathyroidism type 1b: bone histomorphometric analysis.

Authors:  Anne Marie Sbrocchi; Frank Rauch; Margaret L Lawson; Stasia Hadjiyannakis; Sarah Lawrence; Murat Bastepe; Harald Jüppner; Leanne Marie Ward
Journal:  Eur J Endocrinol       Date:  2010-11-09       Impact factor: 6.664

9.  Cystinosis with sclerotic bone lesions.

Authors:  S Sirrs; P Munk; P I Mallinson; H Ouellette; G Horvath; S Cooper; G Da Roza; D Rosenbaum; M O'Riley; G Nussbaumer; L N Hoang; C H Lee
Journal:  JIMD Rep       Date:  2013-10-06

10.  Pseudohypoparathyroidism type 1B in a patient conceived by in vitro fertilization: another imprinting disorder reported with assisted reproductive technology.

Authors:  Nicholas J Goel; Laura L Meyers; Myrto Frangos
Journal:  J Assist Reprod Genet       Date:  2018-02-07       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.